By Nick Stride
Friday 7th March 2003 |
Text too small? |
Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.
It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.
The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.
Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.
British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.
No comments yet
SML - Synlait Milk Limited - Trading Halt of Securities
AIA - Auckland Airport announces board chair changes
AIA - Auckland Airport announces board chair changes
CEN - Tauhara commissioning progress update
FPH initiates voluntary limited recall
March 28th Morning Report
KFL Celebrates 20 Years of Excellence in Investment Mgmt.
SVR - Savor FY24 Earnings Guidance & Change in Banking Partner
NZK - NZ King Salmon Investments Limited FY24 Results
March 27th Morning Report